Patents Represented by Attorney John S. Saxe
  • Patent number: 4863969
    Abstract: 1,2,3,4-Tetrahydro-1,1,4,4-tetramethyl-6-(.alpha.-methylstyryl)naphthalene possesses antihyperplastic, antimetaplastic, antineoplastic tumor-preventative and tumor-therapeutic properties and can accordingly be used in the treatment of precancerous or premalignant lesions as well as in the treatment of malignant tumors of epithelial and mesenchymal nature.
    Type: Grant
    Filed: March 4, 1988
    Date of Patent: September 5, 1989
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Werner Bollag
  • Patent number: 4687859
    Abstract: A novel process for the manufacture of the optically active lactone of the formula ##STR1## is described.
    Type: Grant
    Filed: May 15, 1985
    Date of Patent: August 18, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Horst Pauling, Christof Wehrli
  • Patent number: 4512924
    Abstract: Novel compounds of the formula ##STR1## wherein B represents a methylene, ethylene or vinylene group, R.sup.1 represents a hydrogen atom or an alkyl, aralkyl, amino-alkyl, mono-alkylamino-alkyl, dialkylaminoalkyl, acylamino-alkyl, phthalimido-alkyl, alkoxycarbonylamino-alkyl, aryloxycarbonylamino-alkyl, aralkoxycarbonylamino-alkyl, alkylaminocarbonylamino-alkyl, arylaminocarbonylamino-alkyl, aralkylaminocarbonylamino-alkyl, alkylsulphonylamino-alkyl or arylsulphonylamino-alkyl group, R.sup.2 represents a carboxyl, alkoxycarbonyl or aralkoxycarbonyl group or a group of the formula ##STR2## R.sup.3 represents a carboxyl, alkoxycarbonyl or aralkoxycarbonyl group, R.sup.4 and R.sup.5 each represent a hydrogen atom or R.sup.4 and R.sup.5 together represent an oxo group, R.sup.6 and R.sup.7 each represent a hydrogen atom or an alkyl or aralkyl group or R.sup.6 and R.sup.
    Type: Grant
    Filed: May 12, 1983
    Date of Patent: April 23, 1985
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael R. Attwood, Cedric H. Hassall, Robert W. Lambert, Geoffrey Lawton, Sally Redshaw
  • Patent number: 4452904
    Abstract: This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDFP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.
    Type: Grant
    Filed: August 13, 1981
    Date of Patent: June 5, 1984
    Assignee: Duke University
    Inventor: Darrow E. Haagensen, Jr.